- Balmain, Australia-based Benitec Biopharma (NASDAQ:BNTC) is set for its IPO of 5M American Depositary Shares (ADSs). Each ADS represents 20 ordinary shares. The company currently trades on the Australian Securities Exchange under the symbol "BLT." The estimated price per ADS will be ~$13.00.
- The clinical stage biotech is developing a proprietary therapeutic technology platform called DNA-directed RNA interference (ddRNAi) that combines gene silencing and gene therapy. Its goal is to provide a "one shot" cure for a variety of diseases via the long-term silencing of disease-causing genes. Its pipeline programs target hepatitis C, hepatitis B, age-related macular degeneration, drug-resistant non-small cell lung cancer and oculopharyngeal muscular dystrophy.
-
2014 Financials (A$M): Total Revenues: 1.4 (-6.2%); Operating Expenses: 8.9 (+79.1%); Net Loss: (7.0) (-101.8%); Cash Burn: (9.3) (-239.2%).